Shares of Molecular Partners Inc. MOLN, -36.67% slid 37.3% in premarket trading on Wednesday, the day after the company said Amgen Inc. AMGN, -0.91% returned the global rights to an investigational oncology therapy currently in a Phase 1 clinical trial targeting solid tumors. Amgen's stock was up 0.3% in the premarket on Wednesday.